Genmab — April 2021

[kkjoel]

Btw, I had Deutsche with a previous target on 1580 from 20.02.2020. I suppose they later on at some point officially discontinued the coverage, as the newsitem says: "Genmab/Deutsche Bank: Indleder med.."?!

[Doublo]

God morgen...giver J&J regnskab før Børsåbning salgstal på salg af Darzalex m.m.

[kkjoel]

Blue Skye: could be a tremendous day we have in store.. 2 "raised" targets and better than expected sales from J&J!

[kkjoel]

Maybe "Local Blue Sky" is the more correct express...

[E_L]

that is also the last one i have for Deutsche, i assume it means they have a new analyst

[Helge_LarsenPI-redaktør]

Aktier/tendens: Genmab, Netcompany og banker i fokus på stille dag https://www.proinvestor.com/investornyt/674201/aktier-tendens-genmab-netcompany-og-banker-i-fokus-pa-stille-dag

[Bulder]

Jeg ville gerne kende Deutsches vurdering af voldgitssagen.

[JørgenVarnæs]

Umiddelbart virker det til, at kontrakten er lavet over en slags standardformular for royalty agreements. Mange af kontraktens specifics er overstregede - og offentligheden har derfor ikke adgang til den egentlige ordlyd. Enhver vurdering af sagen lader til at være mere holdning end egentlig substans

[deleted-user]

Nogen må have moret sig bekosteligt den første time her til morgen

[E_L]

that is fast for a change...: NICE says yes to Novartis’ multiple sclerosis therapy Kesimpta https://pharmaphorum.com/news/nice-says-yes-to-novartis-multiple-sclerosis-therapy-kesimpta/

[JørgenVarnæs]

NICE says yes - truly revolutionary. Are they giving Kesimpta away for free?

[E_L]

I doubt that... surely Novartis will mention something on their Q1

[Plimsoller]

Hvem tør skyde på Q1 dara tal fra J&J?

[B.Andersen]

Er det kl. 12?

[Plimsoller]

Ca. 12:40

[B.Andersen]

Tak Plimsoller.

[Plimsoller]

Velbekomme. Informationen kom fra GB i går 07:57, så "kreditten" går til, ham.

[E_L]

Johnson & Johnson Reports 2021 First-Quarter Results:

/PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2021. "Johnson & Johnson delivered a strong first quarter performance...

(www.prnewswire.com)

[E_L]

1.365

[E_L]

US 691 ROW 674